Cargando…
Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients
Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevat...
Autores principales: | Kimura, M, Tomita, Y, Imai, T, Saito, T, Katagiri, A, Tanikawa, T, Takeda, M, Takahashi, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363168/ https://www.ncbi.nlm.nih.gov/pubmed/10408413 http://dx.doi.org/10.1038/sj.bjc.6690576 |
Ejemplares similares
-
Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
por: Yamana, K, et al.
Publicado: (2005) -
Signaling through the Death Receptor CD95 (APO-1/FAS)
por: Peter, Marcus E.
Publicado: (2001) -
Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma
por: Maruyama, R, et al.
Publicado: (2006) -
Deficient activation of CD95 (APO-1/ Fas)-mediated apoptosis: a potential factor of multidrug resistance in human renal cell carcinoma
por: Ramp, U, et al.
Publicado: (2000) -
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage
Publicado: (1995)